Case... October 2008
AERAS GLOBAL TB VACCINE: R&D COOPERATION WITH STATENS SERUM INSTITUT & MEDICON
Why Denmark? "At Aeras, we work by identifying the most promising new TB vaccine candidates and forming joint teams with scientific groups to develop them. One of these development partnerships is with the Statens Serum Institut (SSI), one of the world’s leading scientific organisations working on TB vaccines. Aeras and SSI are working together to develop a vaccine called HyVac 4, which was invented by SSI. We think this candidate is quite promising, and we are enormously pleased to be joining SSI to develop the vaccine." Dr. Jerald Sadoff, President and CEO, Aeras Global TB Vaccine Foundation
Aeras Global TB Vaccine Foundation is a non-profit organization dedicated to developing new TB vaccines and ensuring their availability to all who need them. Aeras is funded by a grant from the Bill & Melinda Gates Foundation and receives additional funding from several other public and private donors.
CASE: AERAS GLOBAL TB VACCINE R&D COOPERATION WITH SSI & MEDICON
The reasons for choosing Denmark: • Denmark is a world leader in vaccine development and production • Access to prominent scientists in the field of TB and vaccines • The opportunity to join Statens Serum Institut in bringing forward the research on the HyVac 4 TB vaccine • Access to Statens Serum Institute’s state of the art vaccine research and production facilities • Experienced and well-respected environment of clinical research organizations • Medicon’s (Danish clinical research organization) experience with preparing and conducting clinical trials around the world
I nt .
sa le
s
R e s e a r ch
P r od u
c ti o
n
ing t test rke Ma
Biz Solutions
De
pm
n
en
t
si g
App
l ica ti o n
De
ve
lo
In April 2005, Aeras Global TB Vaccine initiated research cooperation with the Danish government research institution and vaccine manufacturer Statens Serum Institute (SSI) – a world leader when it comes to TB vaccine research. The research alliance between Aeras and SSI means that a further 14 researchers will be working solely on the development on the promising HyVac 4 TB vaccine. The research cooperation between Aeras and Danish partners also includes mentoring and training by the Danish clinical research organization Medicon in an epidemiological study conducted in South Africa by Aeras and the University of Cape Town.
Denmark at a glance • World's Best Place to conduct business in a five year perspective (Economist Intelligence Unit 2005 & 2006) • Top 5 on the world competitiveness overall scoreboard (IMD 2006) • No 3 in the world on the basis of flexible labour regulations (IMD 2006) • No 1 in the world on E-readiness (The Economist & IBM, 2006) • Highest worker motivation in the world (IMD 2006) • No. 4 in the world on availability of venture capital for business development (IMD 2006)
Whether your company considers to relocate, consolidate, set up new production facilities, is on the lookout for new innovation partners or other strategic business solutions in Europe, Invest in Denmark is a good place to begin. We provide customised information and services free of charge and in full confidentiality.
Invest in Denmark 2, Asiatisk Plads DK-1448 Copenhagen K Tel. +45 33 92 11 16 Fax +45 33 92 07 17